ArticleNature2020
Distinct viral reservoirs in individuals with spontaneous control of HIV-1.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 274 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
274citing papers in PubMed, 2 pooled it
34.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
274 citing papers in PubMed, 2 syntheses or guidelines pooled it, 407 citations in OpenAlex.
- Reservoir differences across HIV-1 subtypes: a systematic review to guide cure research.Frontiers in immunology · 2026Pooled it
- Specialized DNA Structures Act as Genomic Beacons for Integration by Evolutionarily Diverse Retroviruses.Viruses · 2023Pooled it
- MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.The Journal of clinical investigation · 2026Trial
- Intact and Defective HIV Provirus Changes During Antiretroviral Therapy in People Treated During Acute or Chronic HIV Infection or as HIV Controllers.Open forum infectious diseases · 2025Trial
- Trial
- Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.Science translational medicine · 2023Trial
- Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy.Nature immunology · 2026Article
- HIV DNA and transcription before and after ART in natural controllers compared to noncontrollers.Journal of virology · 2026Article
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.Nature medicine · 2026Article
- Single-cell analysis of HIV expression and integration sites reveals robust viral expression across diverse chromatin environments.Microbiology spectrum · 2026Article
- CD4-directed nanoblades enable selective genome editing in CD4EMBO molecular medicine · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Hiding in Plain Sight: HIV-1 Membraneless Organelles as Nuclear Hubs-Host Hijacking, Replication, Immune Evasion, and Drug-Access Implications.Pathogens (Basel, Switzerland) · 2026Review
- NK-like and networked CD8bioRxiv : the preprint server for biology · 2026Article
- The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive Chromatin.bioRxiv : the preprint server for biology · 2026Article
- Is the molecular microenvironment of the latent HIV reservoir predictable using deep learning approaches?Journal of virology · 2026Review
- HIV controllers, lessons learnt from the lymphoid tissues.Current opinion in HIV and AIDS · 2026Review
214 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors at 9 institutions in 1 country.
Chenyang Jiang *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9586-8416
Xiaodong Lian *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6163-9452
Ce Gao *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3775-790X
Xiaoming SunRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Kevin B EinkaufRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7123-1293
Joshua M ChevalierRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8873-6669
Samantha M Y ChenRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7876-4428
Stephane HuaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2244-5663
Ben RheeRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Kaylee ChangRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Jane E BlackmerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Matthew OsbornRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Michael J PelusoDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Rebecca HohDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Ma SomsoukDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Jeffrey MilushDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Lynn N BertagnolliDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sarah E SweetDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Joseph A VarrialeDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Peter D BurbeloDental Clinical Research Core, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.
Tae-Wook ChunNational Institute of Allergies and Infectious Diseases, Bethesda, MD, USA.
Gregory M LairdAccelevir Diagnostics, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2873-4295
Erik SerraoDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alan N EngelmanDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mary CarringtonRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2692-2180
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Janet M SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven G DeeksDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6371-747X
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6122-9245
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. xyu@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-8295-884X
Ragon Institute of MGH, MIT and Harvard · USBrigham and Women's Hospital · USUniversity of California, San Francisco · USHoward Hughes Medical Institute · USJohns Hopkins University · USHarvard University · USBroad Institute · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US
Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MVaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEKALY, RAFICK PIERRE · 2011 to 2015
$29.5MDelaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MCombined Immunologic Approaches to Cure HIV-1UM1AI126603 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., MELLORS, JOHN W · 2016 to 2020
$23.6MNuclear Localization of HIV-1 Preintegration ComplexesR01AI052014 · NIAID · DANA-FARBER CANCER INSTITUTE · PI ENGELMAN, ALAN N. · 2003 to 2025
$11.4MA Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7MA clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4MPathogenesis of Clade C HIV InfectionR37AI067073 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2011 to 2020
$6.6MTraining in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4MCCR NIH HHS HHSN261200800001CHoward Hughes Medical InstituteNCI NIH HHS HHSN261200800001ENHLBI NIH HHS R01 HL134539NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI052014NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI098487NIAID NIH HHS R01 AI120008NIAID NIH HHS R01 AI130005NIAID NIH HHS R21 AI116228NIAID NIH HHS R33 AI116228NIAID NIH HHS R37 AI067073NIAID NIH HHS R44 AI124996NIAID NIH HHS T32 AI007386NIAID NIH HHS T32 AI060530NIAID NIH HHS U01 AI114235NIAID NIH HHS U01 AI117841NIAID NIH HHS U01 AI135940NIAID NIH HHS U19 AI096109NIAID NIH HHS U24 AI143502NIAID NIH HHS UM1 AI126603NIAID NIH HHS UM1 AI126611NIAID NIH HHS UM1 AI126620NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034NIDDK NIH HHS R01 DK120387NIH HHS AI052014NIH HHS AI078799NIH HHS AI098487NIH HHS AI114235NIH HHS AI116228NIH HHS AI117841NIH HHS AI120008NIH HHS AI135940NIH HHS DA047034NIH HHS DK120387NIH HHS HL134539
Abstract
Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of infected individuals (here termed 'elite controllers'), despite the presence of a replication-competent viral reservoir
Indexed as
Gene SilencingAdultAgedCentromereChromosomes, Human, Pair 19DNA, SatelliteFemaleGenome, ViralHeterochromatinHIV-1HIV InfectionsHumansMaleMiddle AgedProvirusesRepressor ProteinsDNA, SatelliteHeterochromatinRepressor ProteinsZNF350 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.